Zentalis Pharmaceuticals
ZNTL
120 hedge funds and large institutions have $2.1B invested in Zentalis Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 54 increasing their positions, 19 reducing their positions, and 10 closing their positions.
457% more call options, than puts
Call options by funds: $5.39M | Put options by funds: $969K
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
250% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 10
184% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 19
33% more capital invested
Capital invested by funds: $1.58B → $2.1B (+$527M)
26% more funds holding
Funds holding: 95 → 120 (+25)
8.44% more ownership
Funds ownership: 88.52% → 96.96% (+8.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$117M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$48M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.1M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$27M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$96.2M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$22M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$14.2M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$8.81M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$7.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AA
126
AlphaCentric Advisors
San Juan,
Puerto Rico
| – | -$217K | -5,000 | Closed |
|
|
BAM
127
Blueshift Asset Management
Red Bank,
New Jersey
| – | -$212K | -4,886 | Closed |
|
128
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$179K | -4,225 | Closed |
|
129
Pacer Advisors
Malvern,
Pennsylvania
| – | -$66K | -1,530 | Closed |
|
ZNTL Hedge Fund Activity: Q2 2021 in Review
120 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q2 2021, worth a combined $2.1B — up 33% from $1.58B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ZNTL positions and 10 closed out — a net gain of 25 holders — while 54 added to existing stakes and 19 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $117M. The largest seller was Redmile Group, cutting an estimated $96.2M.
- 120 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q2 2021, up from 95 in Q1 2021.
- Funds reported $2.1B of Zentalis Pharmaceuticals stock for Q2 2021, up 33% quarter-over-quarter.
- 35 funds opened new Zentalis Pharmaceuticals positions in Q2 2021 and 10 closed out, a net change of +25 holders.
- The largest Zentalis Pharmaceuticals buyer in Q2 2021 was T. Rowe Price Associates, an estimated $117M added.
- The largest Zentalis Pharmaceuticals seller in Q2 2021 was Redmile Group, an estimated $96.2M sold.
Based on aggregated 13F filings for Q2 2021.